Form 4: Gilead Sciences Executive Reports Stock Transactions
SEC Form 4 Filing
Johanna Mercier, Chief Commercial Officer of Gilead Sciences, reports the vesting and disposal of restricted stock units.
Summary
- On September 10, 2024, Johanna Mercier, Chief Commercial Officer of Gilead Sciences, exercised restricted stock units.
- A total of 3,752 shares of common stock were acquired upon vesting of the restricted stock units.
- Ms. Mercier disposed of 1,734 shares of common stock at a price of $81.44 per share to cover tax obligations.
- Following these transactions, Ms. Mercier directly owns 107,484 shares of common stock and 39,945 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common for executives at publicly traded companies. These transactions are closely watched by investors for signals about management's confidence in the company's future prospects.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they represent a small fraction of the total outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 09/10/2024 | Date of transaction: vesting of restricted stock units and disposal of shares. |
| 09/11/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.